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Abstract
Purpose We evaluated the safety and clinical outcomes of a
single local administration of gelatin hydrogel impregnated
with recombinant human fibroblast growth factor (rhFGF)-2
for the treatment of the precollapse stage of osteonecrosis of
the femoral head (ONFH).
Methods Patients with ONFH (precollapse stage ≤2) received
a single local administration of 800 μg of rhFGF-2-
impregnated gelatin hydrogel and were followed up for
one year. The surgery was performed using a minimally inva-
sive technique involving a 1-cm skin incision, and walking was
allowed from day one postoperatively. The primary outcomes
included occurrence of adverse events and complications. The
secondary outcomes included changes in the Harris hip scores,
visual analog scale for pain scores, University of California,
Los Angeles (UCLA) activity scores, and radiological images.
Results We included ten patients, of which five experienced
14 adverse events, including one complication from spinal
anesthesia. However, patients completely recovered from all
adverse events. The mean clinical scores significantly
improved by one year postoperatively compared with the
pre-operative scores (before vs. after: visual analog score for
pain, 21.2 vs. 5.3 mm;UCLA activity score, 5.5 vs. 6.6; Harris
hip score, 81.0 vs. 96.9 points). There was only one case of
femoral head collapse; however, this occurred in a hip with
extensive necrosis. Stage progression and collapse did not
occur in the other nine cases. Computed tomography con-
firmed bone regeneration in the femoral heads.
Conclusions Clinical application of rhFGF-2-impregnated
gelatin hydrogel for patients with precollapse ONFH was fea-
sible and safe.
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Introduction
Osteonecrosis of the femoral head (ONFH) is a multifactorial
disease that can cause femoral head collapse, pain, gait disor-
ders, and secondary hip osteoarthritis. Several causative fac-
tors have been indicated, including hypercoagulation, bone
marrow fat embolisms, elevated internal pressure in the fem-
oral head, and vascular endothelial dysfunction; however, the
cause has not yet been elucidated completely. ONFH is com-
mon among young people in their 30s and 40s, and it bilater-
ally occurs in approximately 50 % cases.
Magnetic resonance imaging (MRI) can be useful for early
diagnosis; however, initial-stage symptoms are usually mild,
with pain intensifying after femoral head collapse. In the clinic,
although patients are diagnosed, 70–80 % of untreated patients
experience femoral head collapse and have to undergo total hip
arthroplasty (THA) [1]. Thus, research over the past decade has
focused on identifying a minimally invasive regenerative ther-
apy that can help prevent femoral head collapse [2, 3].
Therapies using cells, proteins, and other bone growth-
promoting substances have been proposed, and various types
of autologous marrow cell therapy have been used [4–6]. Fur-
thermore, non-cellular therapeutic strategies that use growth
factors have also been proposed [2, 3, 7, 8]. In an animal study
using adult rabbits, we reported that a single local administra-
tion of gelatin hydrogel impregnated with recombinant human
fibroblast growth factor (rhFGF)-2 not only promoted the re-
generation of the necrotic bone but also suppressed the pro-
gression of ONFH [9].
The aim of this preliminary clinical study was to evaluate
the safety and efficacy of a single local administration of
rhFGF-2-impregnated gelatin hydrogel for the treatment of
the pre-collapse stage of ONFH in humans. Here we provide
a summary report of the trial and the short-term results.
Materials and methods
Ethics
The treatment protocol was approved by the Ethics Commit-
tee of Kyoto University Graduate School and Faculty of
Medicine. Before enrollment, written informed consent was
obtained from each participant included in the study. The
study was registered with the public Japanese clinical trials
registry, the University Hospital Medical Information Net-
work Clinical Trials Registry (UMIN000009250).
Study design
We designed this phase II, prospective, open-label clinical trial
to evaluate the safety and clinical outcomes of a single local
administration of rhFGF-2-impregnated gelatin hydrogel as a
treatment for the precollapse stage of ONFH. The study was
conducted at a single institution over 12 months, with patients
enrolled and treated between March 1, 2013, and March 27,
2013, with follow-up ending on June 19, 2014.
Patients
The eligibility criteria were age between 20 and 80 years and
presence of ONFH at precollapse stage 1 or 2 according to the
classification system for ONFH staging developed by the Jap-
anese Investigation Committee of Health and Welfare
(JICHW) [10]. Factors underlying ONFH were determined
as associated with steroid use, associated with alcohol intake,
or idiopathic.
Surgical technique and rehabilitation
Patients were placed in the supine position on a fracture oper-
ation table with a C-arm image intensifier. A 1-cm skin incision
was created over the lateral aspect of the femur near the level of
the lesser trochanter, and 800 μg of rhFGF-2-impregnated gel-
atin hydrogel was embedded percutaneously. In brief, under
fluoroscopic control, a 2.4-mm Kirschner guide wire was
inserted in the direction of the ONFH lesion. The first drilling
was carefully directed to the center of the ONFH region using a
C-arm image based on preoperative planning. With a soft-
tissue protector in place, core decompression was performed
via the guide wire with a 4.8-mm diameter trephine. A 3.5-mm
cylinder was inserted into the core decompression site, and the
hydrogel was inserted in the ONFH region using a special
pusher (Iso Medical Systems, Tokyo, Japan).
Weight bearing was prohibited on the day of surgery; how-
ever, walking was encouraged under the guidance of physical
therapists on day one post-operatively. Before treatment, the
physical therapist assessed walking capability, including pas-
sive hip motion, in all participants.
Preparation of rhFGF-2-impregnated gelatin hydrogel
Recombinant hFGF-2was provided byKaken Pharmaceutical
Co. (Tokyo, Japan). For controlled-release, biodegradable gel-
atin hydrogel was prepared using glutaraldehyde cross-linking
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of acidic gelatin purified from natural bovine bone, as reported
previously [11, 12].
Safety assessment
Safety was monitored by the Department of Clinical Trial
Design and Management Translational Center according to
the occurrence and severity of adverse events (AEs). AEs
were defined as any sign of worsening of the patients’ condi-
tion after treatment, and they were classified as either serious
or non-serious. AEs requiring hospitalization were classified
as serious and were reported and assessed by an external data
monitoring committee, with the severity classified as mild,
moderate, or severe. Causal relationships between the clinical
trial and resolution of each AE were judged and evaluated.
Clinical assessment
All participants underwent preoperative clinical assessment,
and they were prospectively followed-up clinically and radio-
graphically. Patients were evaluated at day one, three, six, and
12 months post-operatively. The primary endpoint was safety
assessment, and the secondary endpoints were changes in the
clinical scores, radiographic stage of ONFH, and bone regen-
eration as evaluated by radiography, computed tomography
(CT), and MRI.
The following clinical score tools were used at baseline
(pre-operative) and at three, six, and 12 months (post-opera-
tively). Patients were evaluated using the visual analog scale
(VAS) for pain, the University of California, Los Angeles
(UCLA) activity score [13], and the Harris hip score (HHS)
[14]. VAS for pain is a self-assessment scale for patients,
which ranges from 0 mm (no pain) to 100 mm (maximum
pain). The UCLA activity score uses a simple scale ranging
from 1 to 10. A rating of 1 is defined as Bno physical activity,
dependent on others^ and 10 is defined as Bregular participa-
tion in impact sports.^ HHS ranges from 0 to 100.025 points,
with higher scores indicating better outcomes, and has the
following subcategories: pain (44 points), limp (11 points),
support (11 points), distance walked (11 points), sitting (5
points), stairs (4 points), putting on shoes and socks (4 points),
absence of deformity (4 points), and range of motion (5.025
points). HHS for range of motion was assessed by a physical
therapist. For patients with bilateral hip involvement, both
hips were examined.
Radiographic assessment
Serial anteroposterior and frog lateral radiographs of the af-
fected hip were used to examine radiographic progression of
the femoral head collapse in hips (before surgery to one year
follow-up) according to each JICHW classification stage. The
JICHW stage and type classifications were used to describe
ONFH and localization of the necrotic lesion [10]. During pre-
operative planning, the drilling route to the necrotic lesion was
planned using navigation software (Orthomap 3D, Stryker,
Kalamazoo, MI, USA; Fig. 1). This software was used to
evaluate bone regeneration at the implanted area of the femo-
ral head. The fraction of osteonecrotic volume to the whole
femoral head was calculated using integrated data from CT
andMRI scans. To clarify the location of bone regeneration in
CT images, further radiological analysis (not included in the
protocol of the clinical trial) was performed. The coronal CT
images obtained pre-operatively were compared with those
obtained at the one year post-operative follow-up after
converting into a binary data format using Image J software
(U.S. National Institutes of Health, Bethesda, MD, USA). For
evaluating binary format data, thresholds for each specimen
were determined at the same condition used to clarify if and
where the bone regenerated. The difference in the two binary
format images was defined as the regenerated bone region, as
described previously [9].
Statistical analysis
All statistical analyses were performed on an intention-to-treat
basis. Safety and efficacy analyses were conducted on all pa-
tients who received treatment. The incidence of AEs and base-
line characteristics were described for each patient. The
changes over time in the VAS for pain scores, UCLA activity
scores, and HHSs were summarized and investigated using a
repeated-measures linear mixed-effect model containing
terms for time with a compound symmetry covariance struc-
ture [15]. The effect of time was analyzed with a one-tailed t-
test. Advances in the disease stage and the incidence of fem-
oral head collapse were evaluated for each patient by radio-
graphic evaluation. Statistical analyses were performed using
SAS version 9.3 software (SAS Institute, Inc., Cary, NC,
USA). All data are reported as mean ± standard deviation.
The linear mixed-effect model was used for statistical analy-




We included five men (five hips) and five women (five hips),
with a mean age of 39.8 years (range: 29–53 years) at the time
of surgery (Table 1). Although eight patients had bilateral
ONFH, three had already undergone THA on the contralateral
side (cases 1, 2, and 8). At the first medical examination, two
patients with bilateral disease (cases 4 and 10) had already
been scheduled for THA on the contralateral side. Eight pa-
tients were receiving treatment with corticosteroid therapy,
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Fig. 1 Representative pre-operative planning and intra-operative
photographs. a A typical screenshot of pre-operative planning is shown.
The yellow area shows the area of osteonecrosis. The surgeon planned the
route and drilling position (blue screw). The planning tool provided
essential guidance for the first drilling, which was critical to the success
of the procedure. The necrosis volume fraction of the femoral head was
calculated by integrating data from magnetic resonance and computed
tomography images. b Preparation of the recombinant human fibroblast
growth factor (rhFGF)-2-impregnated gelatin hydrogel. The gelatin
hydrogel was bottled with a mandatory 30 minute impregnation time
for the rhFGF-2 solution. c Representative pieces of the rhFGF-2-
impregnated gelatin hydrogel. d A representative intra-operative
fluoroscopic image after drilling. e A representative intra-operative
photograph showing administration of the gelatin hydrogel using a
percutaneous technique
Table 1 Patient demographics and baseline characteristics
Case Age/sex Background factors for ONFH Laterality of ONFH
(operated side)
Stage R/L Type R/L Necrosis volume
(percentage)
1 30/F Alcohol intake Bilateral (R) 2/THA A/- 1.8 cm3 (5.1 %)
2 53/F Steroid use (asthma) Bilateral (L) THA/2 -/B 3.0 cm3 (8.3 %)
3 34/F Steroid use (V-K-H synd.) Unilateral (R) 1/- C1/- 10.7 cm3 (25.7 %)
4 35/M Alcohol intake Bilateral (R) 2/3A C2/C2 39.7 cm3 (72.3 %)
5 51/M Steroid use (cutaneous pruritus) Bilateral (R) 2/3A C2/C2 13.3 cm3 (23.5 %)
6 41/M Steroid use (nephrotic syndrome) Bilateral (R) 2/3A C2/C1 23.6 cm3 (41.5 %)
7 29/M Steroid use (AGA) Bilateral (R) 2/3A C2/C1 12.0 cm3 (20.4 %)
8 47/M Steroid use (nephrotic syndrome) Bilateral (R) 2/THA C2/- 11.3 cm3 (23.1 %)
9 32/F Steroid use (SLE) Unilateral (L) -/2 -/C2 9.0 cm3 (26.2 %)
10 46/F Steroid use (SLE) Bilateral (L) 4/2 C2/C2 9.8 cm3 (19.8 %)












Mean: 23.8 cm3 (27.4 %)
Abbreviations: M, male; F, female; ONFH, osteonecrosis of the femoral head; R, right; L, left; THA, total hip arthroplasty; V-K-H synd., Vogt–
Koyanagi–Harada syndrome; AGA, allergic granulomatous angiitis; SLE, systemic lupus erythematosus. Underline indicates the operated side
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and two patients overused alcohol. Stage 1 and 2 disease was
present in one and nine patients, respectively. One patient each
had type A, type B, and type C1 disease, whereas seven pa-
tients had a type C2 lesion. Pre-operatively, the mean necrosis
volume and necrosis volume fraction (percentage of total tis-
sue) was 23.8 cm3 (1.8–39.7 cm3) and 27.4 % (5.1 %–
72.3 %), respectively.
Safety
We evaluated all patients over a one year follow-up period
(Table 2). Fourteen AEs were experienced by five patients
during the observation period. There were two serious AEs,
classified to be of moderate severity (cases 4 and 10), in which
the contralateral side was diagnosed as advancing to above
stage 3 and ONFH. However, these were not associated with
the clinical trial, and the patients had already been scheduled
for THA. Regarding causal relationships, one patient (case 10)
was judged to have developed headache due to spinal anes-
thesia. In all cases, the patients recovered from these AEs over
the follow-up period. There were no complications related to
the surgical technique.
Clinical outcomes
All procedures were performed under spinal anesthesia. The
mean operation time was 18 minutes, the skin incision was
1 cm, there was little bleeding, walking was encouraged from
day one post-operatively, and the mean hospital stay was
6.2 days (range: 5–7 days). Embedding of the rhFGF-2-
impregnated gelatin hydrogel in the necrotic area was con-
firmed in all cases. The mean clinical scores improved signif-
icantly by one year post-operatively (VAS for pain, 5.3 mm;
UCLA activity score, 6.6; HHS, 96.9 points) compared with
pre-operative scores (VAS for pain, 21.2 mm; UCLA activity
score, 5.5; HHS, 81.0 points) (Table 3).
Radiographic evaluation
Although one patient (case 4) developed femoral head col-
lapse (10 %) at the one year post-operative follow-up, this
patient had the greatest necrosis volume fraction. Moreover,
based on post-operative CT images obtained at day one post-
operatively, femoral head collapse was considered to have
progressed from an early collapse that had already been pres-
ent at the time of surgery.
The remaining nine patients neither showed progression of
pre-operative ONFH nor did they exhibit femoral head col-
lapse during the follow-up period. Changes in the necrosis
volume fraction and ONFH type were not observed in the
necrotic areas byMRI; however, there was evidence of homo-
geneous low-signal areas in postoperative T1-weighted im-
ages of the femoral heads (Fig. 2). In radiographs and CT
scans, bone regeneration was observed in the necrotic regions
in all cases. Additional radiographic assessment using binary
format images showed regeneration of the trabecular bones
and subchondral bone (Fig. 3).
Discussion
The minimally invasive treatment described in this study
aimed to prevent femoral head collapse by direct local admin-
istration of rhFGF-2, which has both angiogenic and osteo-
genic actions. To the best of our knowledge, there have been
Table 2 Adverse events
No. Adverse events Degree of seriousness Level of severity Outcome
2 Muscle contusion Non-serious Moderate Recovered
3 Chronic gastritis Non-serious Mild Recovered
3 Panic disorder Non-serious Mild Recovered
3 Loss of hair Non-serious Mild Recovered
3 Cystitis Non-serious Mild Recovered
4 AST and ALT elevation Non-serious Mild Recovered
4 Pain on the opposite side Non-serious Mild Recovered
4 Pain on the affected side Non-serious Mild Recovered
4 Pain on the affected side Non-serious Mild Recovered
4 THA on the opposite side Serious Moderate Recovered
7 Cough Non-serious Mild Recovered
10 Headache Non-serious Mild Recovered
10 Herpes Non-serious Mild Recovered
10 THA on the opposite side Serious Moderate Recovered
Abbreviations: No., patient number; THA, total hip arthroplasty; AST, aspartate aminotransferase; ALT, alanine
transaminase.
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no previous reports regarding the administration of rhFGF-2-
impregnated gelatin hydrogel into the femoral head.
During the one year follow-up period, 14 AEs occurred in
five patients, and all recovered without problems. There were
no complications related to either the surgical technique or
treatment. Moreover, all clinical scores related to pain, daily
activity rating, and hip joint functions significantly improved
post-operatively. Although one patient with stage 3A disease
at surgery (case 4) developed early femoral head collapse that
was present on CT images at day one post-operatively, no
other patients showed disease progression or femoral head
collapse. Thus, local administration of rhFGF-2 was safe.
Therapies using cells [4–6], proteins, and other bone
growth-promoting substances [2, 7, 8] have been proposed,
and various cell therapies using autologous marrow cells are
already being attempted. Non-cellular therapeutic strategies
using growth factors have been proposed; however, there
has been little progress with regard to the verification of ani-
mal experiments, primarily because of the absence of an ani-
mal model for femoral head-specific necrosis [9, 16] and
Fig. 2 Representative magnetic resonance images of the central coronal
plane in the femoral head. a Pre-operative coronal T1-weighted magnetic
resonance imaging (MRI) showing type C2 osteonecrosis of the femoral
head (ONFH) occupying more than the medial two-thirds of the weight-
bearing portion and extending laterally to the acetabular edge. bMRI of
the pre-operative plan described in Fig. 1. c MRI of the same femoral
neck and intertrochanteric region at three months post-operatively,
showing low signal intensity, indicating the drilling route made during
the surgical procedure. dMRI at six months post-operatively showing the
first change of signal intensity in the drilling route. The signal intensity of
bone at the drilling site of the femoral neck is normalizing. e MRI at
12 months post-operatively showing almost normal signal intensity in
the femoral neck. The area and size of ONFH remains unchanged from
type 2. Abbreviations: M, months
Table 3 Clinical outcomes









21.2 ± 24.9 6.1 ± 7.8 5.3 ± 5.5 5.3 ± 8.6 0.002
10.0 (0–84) 3.5 (0–25) 4.5 (0–14) 1.0 (0–27)
UCLA activity
(1–10)
5.5 ± 1.0 6.1 ± 0.7 6.1 ± 0.7 6.6 ± 0.5 <0.001
6 (4–7) 6 (5–7) 6 (5–7) 7 (6–7)
HHS (0–100) 81.0 ± 18.1 94.8 ± 4.0 94.5 ± 7.9 96.9 ± 5.0 <0.001
91.9 (44.9–
96.0)
95.0 (88.0–100.0) 97.0 (74.0–100.0) 100.0 (85.9–
100.0)
Data for each score are expressed as mean ± standard deviation (the upper rows) and median range (the bottom
rows). The P value was calculated for the effect of time in a repeated-measures linear mixed-effect model.
Abbreviations: VAS, visual analog scale; UCLA, University of California, Los Angeles activity; HHS, Harris
hip score
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secondarily because of the lack of a technique to locally de-
liver the growth factor [17]. The angiogenic and osteogenic
actions of rhFGF-2 have been the subject of numerous reports
for bone and joint disease. In particular, when used with gel-
atin hydrogel as a slow-release carrier, treatment with rhFGF-
2 in animal experiments has been shown to increase bone
mass in deficit areas [9, 11, 12]. Release of rhFGF-2 from
the hydrogel at the site of implantation was measurable for
more than 2 weeks, a period that correlates strongly with the
patterns of in vivo rhFGF-2 release and hydrogel degradation
[18]. One human application that merits attention is a report
on single injections of rhFGF-2-impregnated hydrogel at
doses of 200, 400, and 800 μg in cut bone surfaces of the
lower leg, which produced rapid synostosis in a dose-
dependent manner [19, 20].
The most important limitation of the present study is the
lack of a control group using the gelatin hydrogel alone. In
terms of minimally invasive therapies, the simplest technique
is core decompression, which has been used for a long time.
This method creates a burr hole in the femoral head with the
anticipation that self-healing will occur; however, it cannot
ultimately prevent femoral head collapse. High collapse rates
have been reported in up to 72.7 % of femoral heads after use
of core decompression alone [5]. Although it is performed
relatively frequently in Europe and the United States, core
depression is rarely used in Japan unless bone biopsy is nec-
essary. Therefore, it was considered that using a control group
with gelatin hydrogel would present ethical problems in this
clinical trial. Therefore, we simply provided an 800-μg dose
of rhFGF-2, as determined from preclinical experiments using
an animal model of ONFH, without a control group. Other
limitations include the small sample size and short follow-up
period; this was because, as a phase II study and the first
clinical trial in humans, this study was performed mainly to
evaluate safety within a strict budget.
In Europe and the United States, novel therapies have been
developed recently for the management of ONFH, such as
autologous bone marrow cell transplantation and embedding
of metal implant rods. Autologous bone marrow cell trans-
plantation may be reliable for the treatment of the precollapse
stage of ONFH [4–6]. Implantation of cylindrical metal (po-
rous tantalum) rods into the femoral head can prevent collapse
by providing structural support in the necrotic area, which has
been approved as an early-stage therapy [21, 22]. However,
we believe that direct administration of rhFGF-2-impregnated
gelatin hydrogel offers the important advantages of not only
being a minimally invasive percutaneous technique that facil-
itates early return to society but also being able to promote
bone regeneration in necrotic areas. Therefore, with further
development, it could become a useful treatment for the
precollapse stage of ONFH because it can be performed any
time before femoral head collapse, regardless of the cause.
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